**Name of Journal:** *World Journal of Virology*

**Manuscript NO:** 79976

**Manuscript Type:** MINIREVIEWS

**The impact of COVID-19 on liver injury in various age**

Sadeghi Dousari *et al*. Impact COVID-19 on liver injury

Amin Sadeghi Dousari, Seyed Soheil Hosseininasab, Fatemeh Sadeghi Dousari, Masoumeh Fuladvandi, Naghmeh Satarzadeh

**Amin Sadeghi Dousari,** Department of Microbiology, Jiroft University of Medical Sciences, Jiroft 7861634204, Iran

**Seyed Soheil Hosseininasab,** Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman 7616913555, Iran

**Fatemeh Sadeghi Dousari,** Department of Midwifery, Jiroft University of Medical Sciences, Jiroft 7861634204, Iran

**Masoumeh Fuladvandi,** Department of Nursing, Aligoudarz School of Nursing, Lorestan University of Medical Sciences, Khorramabad 6813833946, Iran

**Naghmeh Satarzadeh,** Department of Pharmaceutical Biotechnology, Kerman University of Medical Sciences, Kerman 7616913555, Iran

**Author contributions:** Sadeghi Dousari A, Hosseininasab SS, Sadeghi Dousari F, Fuladvandi M, Satarzadeh N analyzed the data and wrote the manuscript; All authors have read and approve the final manuscript.

**Corresponding author: Naghmeh Satarzadeh, PhD, Researcher,** Department of Pharmaceutical Biotechnology, Kerman University of Medical Sciences, Haft-Bagh Highway, Kerman 7616913555, Iran. n.satarzadeh@kmu.ac.ir

**Received:** September 13, 2022

**Revised:** October 14, 2022

**Accepted:** January 3, 2023

**Published online:** March 25, 2023

**Abstract**

The coronavirus disease 2019 (COVID-19) disease was first detected in December 2019 in Wuhan, China. This disease is currently one of the most important global health problems. The novel coronavirus COVID-19 is a respiratory illness, that has caused a deadly pandemic that is spreading rapidly around the world. It is not only a respiratory system virus that causes severe lung disease, but also a systemic disease agent that can affect all systems. People with COVID-19 disease usually have respiratory signs, however, the liver disorder is not an uncommon presentation. In addition, many studies around the world have revealed that the liver is injured to various degrees in patients with severe acute respiratory syndrome coronavirus 2 disease. This review mainly focuses on the impact of COVID-19 on Liver Injury at various ages.

**Key Words:** Liver injury; Coronavirus disease 2019; Severe acute respiratory syndrome coronavirus 2; Minireview

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Sadeghi Dousari A, Hosseininasab SS, Sadeghi Dousari F, Fuladvandi M, Satarzadeh N. The impact of COVID-19 on liver injury in various age. *World J Virol* 2023; 12(2): 91-99

**URL**: https://www.wjgnet.com/2220-3249/full/v12/i2/91.htm

**DOI**: https://dx.doi.org/10.5501/wjv.v12.i2.91

**Core Tip:** Studies have shown that neonates have rare evidence of liver damage, and in terms of age, they show the least amount of liver damage in the face of coronavirus disease 2019 (COVID-19) among affected people. Also, many studies reported different patterns of liver damage among children with COVID-19 much less than in adults, which is probably related to differences in their innate immune system and adaptation. The highest rate of liver damage is in adult patients and aspartate aminotransferase levels had the highest relevance with mortality compared to other indices reflecting liver injury.

**INTRODUCTION**

Coronaviruses are a big family of viruses belonging to the realm Riboviria, order Nidovirales, family Coronaviridae and subfamily Coronavirinae. This virus contains an RNA genome and belongs to the Coronaviridae family[1,2]. This virus is spread in a wide spectrum of humans, other mammals, and avian species, also inducing acute respiratory infections[3]. Types of coronaviruses including HCoV-NL63, HCoV-HKU1, HCoV-229E, and HCoV-OC43 have been presented as mild virulent human viruses worldwide[4]. These viruses cause mild to severe acute respiratory illnesses in humans[3]. Coronavirus disease 2019 (COVID-19) was identified for the first time in December 2019, in Wuhan, located in the capital of Hubei Province in the People's Republic of China[1]. Coronavirus disease 2019 is an infectious illness that has caused a lethal pandemic that rapidly extends worldwide[5,6]. The signs of COVID-19 appear approximately 5.2 d after the disease and last for a minimum of 41 d and a maximum of 14 d until the end of life[4,7].

In the early stages of COVID-19, it has been found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not only a respiratory system virus that generates severe lung disease but a systemic disease factor that can involve all systems[8,9]. Some extrapulmonary involvement of SARS-CoV-2 disease is in organs like the liver, heart, or kidneys[10]. Many studies throughout the world have demonstrated that the liver is injured to differing degrees in patients affected by SARS-CoV-2 disease[8,9].

The liver is a vital member that is mostly responsible for the storage of glycogen and regulation of blood glucose levels, protein synthesis, metabolism of toxic substances, and very other physiological processes[8,9]. Liver dysfunction has been reported in 54% of hospitalized patients affected by COVID-19 disease, most of which are more severe in COVID-19[11]. Liver injuries have been documented in patients affected by COVID-19, and commonly have mild increasing liver enzymes range from 14% to 53%[12]. Patients with severe disease, especially those hospitalized in ICU, have shown a higher increase in transaminase enzymes than patients with mild to moderate severity[13]. Furthermore, few studies investigated the dynamic change of liver function during the COVID-19 pandemic. Also, no study to date has documented the incidence of a simultaneous increase in liver transaminases and total bilirubin levels in COVID-19 patients[14].

The purpose of this review is to evaluate the effect of COVID-19 on liver injury in various ages.

**Definition of liver Injury**

Patients who make severe acute liver injury in the absence of preexisting chronic liver disease, usually indicate noteworthy liver dysfunction marked with coagulopathy, which is described as an international normalized ratio ≥ 1.5 and is classically defined as acute liver failure (ALF) when any degree of hepatic encephalopathy (HE) is existing[15]. The ALF types include: (1) Hyperacute: < 7 d; (2) Acute: 7–28 d, and (3) Subacute: 28 d to 6 mo, depending on latency between the beginning of signs and development of encephalopathy and coagulopathy[16,17].

**How does COVID-19 cause liver Injury?**

Liver injury is seen in patients with COVID-19, and its harshness is altered depending on the patient's age, geographical area, and disease severity[18]. Viral direct damage[19], immune damage, systemic inflammatory response, drug-induced, ischemia-reperfusion injury, mechanical ventilation, and underlying diseases may donate to liver injury[20] (Figure 1).

There is much evidence that COVID-19 causes abnormal liver function experiment outcomes with increased levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in people with liver damage[21,22]. Studies performed in Wuhan, China, recorded mildly elevated ALT and AST levels in 14%–53% of cases, with higher rates of both enzymes in patients with intense infection, mostly in patients requiring admission to the intensive care unit[23]. In COVID-19 patients with injured biliary tract were increased serum bilirubin, alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT) levels[24]. Also, in cases where the virus causes notable liver injury and intense clinical symptoms, varying levels of ALP and GGT along with high levels of ALT and total bilirubin have been reported in 58%-78% of patients[25].

The pathophysiology of liver damage may include the cytopathic result, in which spike (S) protein of coronaviruses 2019 attaches to the angiotensin-converting enzyme 2 (ACE2) receptor, leading to reduced liver function and hepatobiliary disease[26]. S protein viral entry into the liver cells (hepatocytes and cholangiocytes), a process that involves binding to the surface of the host cell through binding of the surface unit (S1) to a receptor[27,28]. The virus attains access to the host *via* the ACE2 receptor (a type I integral membrane protein containing zinc, which indicates enzymatic action through cleaving the vasoconstrictor peptide angiotensin II to angiotensin I, a strong vasodilator peptide, therefore decreasing blood pressure). ACE2 receptor was abundantly demonstrated in epithelial cells that line a three-dimensional network of bile ducts named cholangiocytes (60%), hepatocytes (3%) in the liver, alveolar cells of the lungs, and in various organs such as the pancreas, kidney, and heart[29,30].

**Factors related to the COVID-19 disease that cause liver damage**

**Drugs:** There are several drugs that prescribed to manage the treatment of patients with COVID-19 and associated symptoms, including therapeutic agents such as antivirals, antibiotics, acetaminophen, immunomodulators, corticosteroids, steroids, and antipyretics, that are metabolized through the liver and their use may lead to hepatotoxicity[31,32]. It has been reported that liver damage caused by these drugs is reason of anomalies in liver experiments and histological variation like micro-vesicular steatosis and liver inflammation in COVID-19 patients. Drugs like oseltamivir, arbidol, hydroxychloroquine, as well as ritonavir, and lopinavir in the treatment of patients may induce variable degrees of hepatotoxicity[33].

**Hypoxia:** Hypoxia in patients with COVID-19 is known as a major factor that causes a decrease in oxygen saturation values and finally reduction in systemic blood pressure[34]. This will ultimately cause a reduction in liver arterial perfusion *via* liver ischemia and hypoxia reperfusion injury *via* liver cell hypoxia[35].

**Cytokines storm:** Another factor related to COVID-19 that causes liver damage is the occurrence of a cytokine storm. In cases of the moderate and severe phase of the disease, which includes endothelial damage, it is related *via* a strong immune response to the SARS-CoV-2 virus[36]. This step is accompanied by the stimulation of inflammasomes (cytosolic multiprotein oligomers) that are responsible for the activation of caspase-1 and the release of pro-inflammatory cytokines [Interleukin (IL)-1β, IL-6, and IL-18][37]. In the next step, these cytokines stimulate the expression of genes relevant to the immune response, and through intracellular signaling, especially using IL-6, other pro-inflammatory cytokine biomarkers like tumor necrosis factor-alpha, IL-2, IL-8, IL-10, IL-17, granulocyte colony-stimulating factor monocyte chemoattractant protein, and interferon-inducible protein [38]. In addition, IL-6 activates numerous downstream signal pathways using creating complexes with its receptor[39], and also the reason for raised ferritin and C-reactive protein levels, reduced lymphocytes and enhanced neutrophils[40].

**Underlying liver diseases:** Underlying liver diseases can aggravate liver damage in the face of COVID-19. The prevalence of underlying liver diseases in patients with COVID-19 has been reported to be between 3% -11% in large observational studies[27,41,42]. From cases of these underlying diseases can be mentioned chronic liver disease and cirrhosis, non-alcoholic fatty liver disease, and liver transplantation[27].

**The association different ages and liver Injury caused by COVID-19**

Many studies have demonstrated various patterns of disease and their outcomes between adults and children, possibly associated with the difference in their innate and adaptive immune systems. Children with or without chronic sickness are less likely to have a severe illness from COVID-19 confirmed in various studies[43]. However, children affected by COVID-19 have a milder infection than adults, possibly related to children having preserved effector and immunosuppressive components[44]. The differences in age, gender, and population are probably due to differences in immune responses and different variants of SARS-CoV-2[45]. Furthermore, children are less likely to have multiple chronic conditions than older people[44]. Children with a weakened immune system, such as liver illnesses considered at higher risk of coronavirus[43]. Some reports showed children to have higher ACE2 expression than older adults, that it conversion ang I (angiotensin I enzyme) into angiotensin 1-7 (ang 1-7) enzyme, thus ang 1-7 enzyme protecting against pulmonary capillary leak and inflammation. This issue can be the reason why children are more resistant to COVID-19 than adults. The mechanism of liver injury in cases by COVID- 19 is indistinct[46]. The liver damage associated with COVID-19 is described as any liver injury happening during the progression and treatment of this disease in cases with or without underlying liver illness[47]. The most common presentation of liver damage in patients is with COVID-19 shown by increasing liver enzymes and also decreasing Serum albumin in severe cases. However, reports of death in affected by COVID-19 patients due to severe liver injury rarely happen[48,49].

**the effects of covid-19 on liver injury in neonates**

A clinical study of 10 neonates (including twins) to 9 born to mothers with COVID-19 showed that only two infants have thrombocytopenia accompanied using abnormal liver function[50]. Clinical Analysis of 48 Neonates Born to Mothers with COVID-19 (confirmed or clinically diagnosed) or without it accomplished by Liu *et al*[51] polymerase chain reaction (PCR) test of all neonates was negative. Evidence of vertical transmission and liver injury was not observed. Similarly, a clinical investigation of 19 neonates born to mothers with COVID-19 was investigated at Tongji Hospital, China. The COVID-19 real-time reverse-transcription–PCR Test of all neonates was negative. In this study also, vertical transfer of SARS-CoV-2 was not found[52]. Wang *et al*[53] investigated a case report of neonates with positive test results for coronavirus 36 h after birth. Nevertheless, whether this Newborn is vertical transfer from the mother to the neonate is yet to be verified. In this case, was observed a significant increase in AST and abnormalities in liver function tests. Stolfi *et al*[54] reported a neonate of vertical transmission of COVID-19 with liver injury, confirmed using an increase in serum transaminases in Italy. The positive PCR test of COVID-19 in a neonate less than 24 h after C-section probably indicates vertical transmission, therefore proposing a transplacental transfer of SARS-CoV-2. Liver damage in this neonate was created probably using a direct virus-mediated mechanism that correlated to ACE2 receptor expression, But the details are unknown. Out of 33 neonates born to mothers affected by COVID-19 in China, three cases have positive PCR tests for COVID-19. One neonate had observed increasing transaminases[55].

**the effects of covid-19 on liver injury in adults**

Guan *et al*[56] extracted information about 1099 patients with positive PCR tests for COVID-19 in 30 provinces in China (from 552 hospitals). Out of 1099 patients, 112 cases (with an average age of 47 years) had a slight increase of AST with mild illness, and 56 adults had a high increase of AST with severe illness. In 2020, in a national retrospective cohort study in France, Mallet *et al*[57] examined the danger of mortality after COVID-19 disease in adult with chronic liver disease. The study contained 259,110 of all adults with COVID-19 who were released from post-acute care and acute, public and private hospitals in France in 2020. From a total of 259,110 patients who were between 54 and 83 years old (average age 70 years) and 52% were men, including 10,006 (3.9%) and 15,746 (6.0%) patients with alcohol use disorders and chronic liver disease, respectively. The results of this study demonstrated that patients with uncompensated cirrhosis, primary liver cancer, and alcohol use disorders were at high risk for COVID-19 fatality, while patients with compensated cirrhosis, mild liver disease, organ, including liver transplant, or acquired depressive syndrome were not at risk of COVID-19 mortality. Overall, mortality was in 38,203 (15%) of the patients, including chronic liver disease 2,941 (19%) and 7,475 (28%) after mechanical ventilation.

In another study, Mantovani *et al*[42] evaluated the widespread outbreak of chronic liver disease among patients affected by COVID-19 with a meta-analysis of data in observational studies and investigating the association between the liver injury and COVID-19 disease. The number of 11 observational studies included 2034 adults aged between 45 and 54 years (average age of 49 years), and 57.2% were men. The results of this study revealed that the widespread outbreak of chronic liver disease was 3% and people with severe disease of COVID-19 had associated changes in liver enzymes and coagulation profiles, which were reported to be possibly due to an innate immune response to the virus. In addition, the findings of this study displayed that the gain in AST level in hospitalized severe patients was more frequent and significant than the gain in ALT, and AST levels had the highest relevance with mortality compared to other indices reflecting liver damage, and it was reported that common factors related with the increase in liver damage indicators were the enhance in the number of neutrophils, the decrease in the number of lymphocytes, and male gender. The association between liver damage and adverse events of Coronavirus disease is indistinct. In adult studies, a higher rate of liver enzymes was reported in adults with severe diseases than in milder diseases[43]. One of the limitations of this study is that it is a retrospective study, which may have inadvertently missed some studies with basic keyword searches. In addition, the mechanism of liver damage at COVID-19 patients with different ages in used studies has not been clarified. However, this study was summarized existing evidence on the effects of COVID-19 on the liver injury at various ages. Furthermore, this study might have helped in clinical diagnosis and treatment for COVID-19related liver disease.

Figure 2 shows a summary of the effects of COVID-19 on Liver Injury at various ages.

**Recommendations and future researches**

The mechanisms of liver damage in either adults or children with COVID-19 are not fully unclear and the impact of liver injury caused by new variants of COVID-19 in patients is unexplained. Furthermore, further investigation is required to determine liver involvement and the consequence of COVID-19 on various ages with liver disease. Also, the pathogenetic mechanisms of COVID-19 on liver injury of patients in different age groups need to be investigated.

**CONCLUSION**

Liver damage is seen in patients affected by COVID-19, and factors including viral direct damage, immune damage, systemic inflammatory response, drug-induced, ischemia-reperfusion injury, mechanical ventilation, and underlying diseases contribute to liver injury. The association between liver damage and adverse clinical outcomes in patients affected by COVID-19 and the mechanism of SARS-CoV-2 in creating this injury is also unclear. Studies have shown that neonates have rare evidence of liver damage, and in terms of age, they show the least amount of liver damage in the face of COVID-19 disease among affected people. Most patients with COVID-19 have maintained their normal liver function during the disease, but patients with more severe disease probably had an abnormal liver function. Also, many studies reported different patterns of liver damage among children with COVID-19 much less than in adults, which is probably related to differences in their innate immune system and adaptation. Most patients with COVID-19 have a mild increase in aspartate aminotransferase, alanine aminotransferase, or total bilirubin. The highest rate of liver damage is in adult patients and AST levels had the highest relevance with mortality compared to other indices reflecting liver injury.

**REFERENCES**

1 **Sadeghi Dousari A**, Taati Moghadam M, Satarzadeh N. COVID-19 (Coronavirus Disease 2019): A New Coronavirus Disease. *Infect Drug Resist* 2020; **13**: 2819-2828 [PMID: 32848431 DOI: 10.2147/IDR.S259279]

2 **Meena P**, Bhargava V, Rana DS, Bhalla AK, Gupta A. COVID-19 and the kidney: A matter of concern. *Curr Med Res Pract* 2020; **10**: 165-168 [PMID: 32839726 DOI: 10.1016/j.cmrp.2020.07.003]

3 **Moghadam MT**, Taati B, Paydar Ardakani SM, Suzuki K. Ramadan Fasting During the COVID-19 Pandemic; Observance of Health, Nutrition and Exercise Criteria for Improving the Immune System. *Front Nutr* 2020; **7**: 570235 [PMID: 33521030 DOI: 10.3389/fnut.2020.570235]

4 **Shakibnia P,** Ahmadi RH, Fallah F, Ebrahimzadeh F, Dosari AS, Mojtahedi A, *et al* Iran as the Center of challenges in the Middle East for the Outbreak of COVID-19 Delta Variant. *Iranian Red Crescent Medical Journal* 2021; **23** [DOI: 10.32592/ircmj.2021.23.11.1394]

5 **Taati B,** Paydar Ardakani SM, Suzuki K, Sadat Modaresi M, Taati Moghadam M, Roozbeh B. Protective Roles of Exercise and Nutritional Factors for Immune System During Delta Variant-COVID-19 Outbreaks: Evidence Review and Practical Recommendations. *Iranian Journal of Medical Microbiology* 2022; **16**: 2345-4342 [DOI:[10.30699/ijmm.16.3.178](http://dx.doi.org/10.30699/ijmm.16.3.178)]

6 **Moghadam MT,** Babakhani S, Rajabi S, Baravati FB, Raeisi M, Dousari AS. Does stress and anxiety contribute to COVID-19? *Iranian Journal of Psychiatry and Behavioral Sciences* 2021; **15** [DOI: 10.5812/ijpbs.106041]

7 **Li Q**, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med* 2020; **382**: 1199-1207 [PMID: 31995857 DOI: 10.1056/NEJMoa2001316]

8 **Kayaaslan B**, Guner R. COVID-19 and the liver: A brief and core review. *World J Hepatol* 2021; **13**: 2013-2023 [PMID: 35070005 DOI: 10.4254/wjh.v13.i12.2013]

9 **Trefts E**, Gannon M, Wasserman DH. The liver. *Curr Biol* 2017; **27**: R1147-R1151 [PMID: 29112863 DOI: 10.1016/j.cub.2017.09.019]

10 **Carvalho T**. Extrapulmonary SARS-CoV-2 manifestations. *Nat Med* 2020; **26**: 1806 [PMID: 33288941 DOI: 10.1038/s41591-020-01162-z]

11 **Davidov-Derevynko Y**, Ben Yakov G, Wieder A, Segal G, Naveh L, Orlova N, Gringauz I, Amit S, Mor O, Klempfner R, Rahav G, Ben Ari Z. The liver in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. *Eur J Gastroenterol Hepatol* 2021; **33**: e313-e319 [PMID: 33653988 DOI: 10.1097/MEG.0000000000002048]

12 **Wang D**, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020; **323**: 1061-1069 [PMID: 32031570 DOI: 10.1001/jama.2020.1585]

13 **Shi H**, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet Infect Dis* 2020; **20**: 425-434 [PMID: 32105637 DOI: 10.1016/S1473-3099(20)30086-4]

14 **Wang Q**, Zhao H, Liu LG, Wang YB, Zhang T, Li MH, Xu YL, Gao GJ, Xiong HF, Fan Y, Cao Y, Ding R, Wang JJ, Cheng C, Xie W. Pattern of liver injury in adult patients with COVID-19: a retrospective analysis of 105 patients. *Mil Med Res* 2020; **7**: 28 [PMID: 32507110 DOI: 10.1186/s40779-020-00256-6]

15 **Koch DG**, Speiser JL, Durkalski V, Fontana RJ, Davern T, McGuire B, Stravitz RT, Larson AM, Liou I, Fix O, Schilsky ML, McCashland T, Hay JE, Murray N, Shaikh OS, Ganger D, Zaman A, Han SB, Chung RT, Brown RS, Munoz S, Reddy KR, Rossaro L, Satyanarayana R, Hanje AJ, Olson J, Subramanian RM, Karvellas C, Hameed B, Sherker AH, Lee WM, Reuben A. The Natural History of Severe Acute Liver Injury. *Am J Gastroenterol* 2017; **112**: 1389-1396 [PMID: 28440304 DOI: 10.1038/ajg.2017.98]

16 **Lemmer P**, Pospiech JC, Canbay A. Liver failure-future challenges and remaining questions. *Ann Transl Med* 2021; **9**: 734 [PMID: 33987432 DOI: 10.21037/atm-20-4968]

17 **Canbay A**, Tacke F, Hadem J, Trautwein C, Gerken G, Manns MP. Acute liver failure: a life-threatening disease. *Dtsch Arztebl Int* 2011; **108**: 714-720 [PMID: 22114640 DOI: 10.3238/arztebl.2011.0714]

18 **Zhao JN**, Fan Y, Wu SD. Liver injury in COVID-19: A minireview. *World J Clin Cases* 2020; **8**: 4303-4310 [PMID: 33083389 DOI: 10.12998/wjcc.v8.i19.4303]

19 **Satarzadeh N,** Behzadi A, Khalilabadi RM. Donors with Positive Hepatitis B and C Infections and Their Demographic Characteristics, a Study in Jirof Blood Donation Center From 2011 to 2016. *Int J Basic Sci Med* 2022; **7**: 57-60. [DOI: 10.34172/ijbsm.2022.10]

20 **Shousha HI**, Ramadan A, Lithy R, El-Kassas M. Patterns of liver profile disturbance in patients with COVID-19. *World J Clin Cases* 2022; **10**: 2063-2071 [PMID: 35321162 DOI: 10.12998/wjcc.v10.i7.2063]

21 **Kukla M**, Skonieczna-Żydecka K, Kotfis K, Maciejewska D, Łoniewski I, Lara LF, Pazgan-Simon M, Stachowska E, Kaczmarczyk M, Koulaouzidis A, Marlicz W. COVID-19, MERS and SARS with Concomitant Liver Injury-Systematic Review of the Existing Literature. *J Clin Med* 2020; **9** [PMID: 32403255 DOI: 10.3390/jcm9051420]

22 **Krishnan A**, Prichett L, Tao X, Alqahtani SA, Hamilton JP, Mezey E, Strauss AT, Kim A, Potter JJ, Chen PH, Woreta TA. Abnormal liver chemistries as a predictor of COVID-19 severity and clinical outcomes in hospitalized patients. *World J Gastroenterol* 2022; **28**: 570-587 [PMID: 35316959 DOI: 10.3748/wjg.v28.i5.570]

23 **Chen N**, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**: 507-513 [PMID: 32007143 DOI: 10.1016/S0140-6736(20)30211-7]

24 **Cai Q**, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y, Liu Y, He Q, Chen J, Liu L, Xu L. COVID-19: Abnormal liver function tests. *J Hepatol* 2020; **73**: 566-574 [PMID: 32298767 DOI: 10.1016/j.jhep.2020.04.006]

25 **McGrowder DA**, Miller F, Anderson Cross M, Anderson-Jackson L, Bryan S, Dilworth L. Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. *Diseases* 2021; **9** [PMID: 34287285 DOI: 10.3390/diseases9030050]

26 **Lozano-Sepulveda SA**, Galan-Huerta K, Martínez-Acuña N, Arellanos-Soto D, Rivas-Estilla AM. SARS-CoV-2 another kind of liver aggressor, how does it do that? *Ann Hepatol* 2020; **19**: 592-596 [PMID: 32858226 DOI: 10.1016/j.aohep.2020.08.062]

27 **McGrowder DA**, Miller F, Anderson Cross M, Anderson-Jackson L, Bryan S, Dilworth L. Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. *Diseases* 2021; **9** [PMID: 34287285 DOI: 10.3390/diseases9030050]

28 **Sariani OK,** Dousari AS, Moghadam MT. Possible psychological consequences in public of Omicron variant (B. 1.1. 529) of SARS-CoV-2 identification in Iran. *Iran J Psychiatry Behav Sci* 2022; **16**: 485-487 [DOI:10.30699/ijmm.16.5.485]

29 **Liu F**, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. *Clin Gastroenterol Hepatol* 2020; **18**: 2128-2130.e2 [PMID: 32334082 DOI: 10.1016/j.cgh.2020.04.040]

30 **Ozkurt Z**, Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. *World J Clin Cases* 2022; **10**: 1140-1163 [PMID: 35211548 DOI: 10.12998/wjcc.v10.i4.1140]

31 **Boeckmans J**, Rodrigues RM, Demuyser T, Piérard D, Vanhaecke T, Rogiers V. COVID-19 and drug-induced liver injury: a problem of plenty or a petty point? *Arch Toxicol* 2020; **94**: 1367-1369 [PMID: 32266419 DOI: 10.1007/s00204-020-02734-1]

32 **D'Ardes D**, Boccatonda A, Cocco G, Fabiani S, Rossi I, Bucci M, Guagnano MT, Schiavone C, Cipollone F. Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship. *World J Gastroenterol* 2022; **28**: 1102-1112 [PMID: 35431501 DOI: 10.3748/wjg.v28.i11.1102]

33 **Marjot T**, Webb GJ, Barritt AS 4th, Moon AM, Stamataki Z, Wong VW, Barnes E. COVID-19 and liver disease: mechanistic and clinical perspectives. *Nat Rev Gastroenterol Hepatol* 2021; **18**: 348-364 [PMID: 33692570 DOI: 10.1038/s41575-021-00426-4]

34 **Sahu T**, Pande B, Pl M, Verma HK. Liver dysfunction during COVID-19 pandemic: Contributing role of associated factors in disease progression and severity. *World J Hepatol* 2022; **14**: 1099-1110 [PMID: 35978661 DOI: 10.4254/wjh.v14.i6.1099]

35 **Sanyaolu A**, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, Hosein Z, Padda I, Mangat J, Altaf M. Comorbidity and its Impact on Patients with COVID-19. *SN Compr Clin Med* 2020; **2**: 1069-1076 [PMID: 32838147 DOI: 10.1007/s42399-020-00363-4]

36 **García LF**. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. *Front Immunol* 2020; **11**: 1441 [PMID: 32612615 DOI: 10.3389/fimmu.2020.01441]

37 **Shah A**. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19. *Front Immunol* 2020; **11**: 1021 [PMID: 32574259 DOI: 10.3389/fimmu.2020.01021]

38 **Costela-Ruiz VJ**, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. *Cytokine Growth Factor Rev* 2020; **54**: 62-75 [PMID: 32513566 DOI: 10.1016/j.cytogfr.2020.06.001]

39 **Gonçalves Júnior J**. COVID-19, liver dysfunction and pathophysiology: A conceptual discussion. *World J Gastroenterol* 2022; **28**: 683-688 [PMID: 35317425 DOI: 10.3748/wjg.v28.i6.683]

40 **Samprathi M**, Jayashree M. Biomarkers in COVID-19: An Up-To-Date Review. *Front Pediatr* 2020; **8**: 607647 [PMID: 33859967 DOI: 10.3389/fped.2020.607647]

41 **Fan Z**, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J. Clinical Features of COVID-19-Related Liver Functional Abnormality. *Clin Gastroenterol Hepatol* 2020; **18**: 1561-1566 [PMID: 32283325 DOI: 10.1016/j.cgh.2020.04.002]

42 **Mantovani A**, Beatrice G, Dalbeni A. Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis. *Liver Int* 2020; **40**: 1316-1320 [PMID: 32329563 DOI: 10.1111/liv.14465]

43 **Di Giorgio A**, Hartleif S, Warner S, Kelly D. COVID-19 in Children With Liver Disease. *Front Pediatr* 2021; **9**: 616381 [PMID: 33777864 DOI: 10.3389/fped.2021.616381]

44 **Dhochak N**, Singhal T, Kabra SK, Lodha R. Pathophysiology of COVID-19: Why Children Fare Better than Adults? *Indian J Pediatr* 2020; **87**: 537-546 [PMID: 32410003 DOI: 10.1007/s12098-020-03322-y]

45 **Forster P**, Forster L, Renfrew C, Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. *Proc Natl Acad Sci U S A* 2020; **117**: 9241-9243 [PMID: 32269081 DOI: 10.1073/pnas.2004999117]

46 **Wu J**, Shi C, Sheng X, Xu Y, Zhang J, Zhao X, Yu J, Shi X, Li G, Cao H, Li L. Prognostic Nomogram for Patients with Hepatitis E Virus-related Acute Liver Failure: A Multicenter Study in China. *J Clin Transl Hepatol* 2021; **9**: 828-837 [PMID: 34966646 DOI: 10.14218/JCTH.2020.00117]

47 **Sun J**, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. *Liver Int* 2020; **40**: 1278-1281 [PMID: 32251539 DOI: 10.1111/liv.14470]

48 **Ji D,** Qin E, Xu J ,Zhang D,Cheng G,Wang Y,Lau G. Implication of non-alcoholic fatty liver diseases (NAFLD) in patients with COVID-19: a preliminary analysis. *J Hepatol* 2020; **73** [DOI: 10.1016/j.jhep.2020.03.044]

49 **Mao R**, Doyon G, Gordon IO, Li J, Lin S, Wang J, Le THN, Elias M, Kurada S, Southern B, Olman M, Chen M, Zhao S, Dejanovic D, Chandra J, Mukherjee PK, West G, Van Wagoner DR, Fiocchi C, Rieder F. Activated intestinal muscle cells promote preadipocyte migration: a novel mechanism for creeping fat formation in Crohn's disease. *Gut* 2022; **71**: 55-67 [PMID: 33468536 DOI: 10.1136/gutjnl-2020-323719]

50 **Word Health Organization.** Opening remarks at the media briefing on COVID-19. [Internet] [accessed March 11, 2020]. Available from:https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020

51 **Liu W**, Cheng H, Wang J, Ding L, Zhou Z, Liu S, Chang L, Rong Z. Clinical Analysis of Neonates Born to Mothers with or without COVID-19: A Retrospective Analysis of 48 Cases from Two Neonatal Intensive Care Units in Hubei Province. *Am J Perinatol* 2020; **37**: 1317-1323 [PMID: 32892325 DOI: 10.1055/s-0040-1716505]

52 **Liu W**, Wang J, Li W, Zhou Z, Liu S, Rong Z. Clinical characteristics of 19 neonates born to mothers with COVID-19. *Front Med* 2020; **14**: 193-198 [PMID: 32285380 DOI: 10.1007/s11684-020-0772-y]

53 **Wang S**, Guo L, Chen L, Liu W, Cao Y, Zhang J, Feng L. A Case Report of Neonatal 2019 Coronavirus Disease in China. *Clin Infect Dis* 2020; **71**: 853-857 [PMID: 32161941 DOI: 10.1093/cid/ciaa225]

54 **Stolfi I**, Conti MG, Marciano A, Dito L, Natale F, Bartolucci M, Cellitti R, Regoli D, Ticchiarelli A, Pangallo I, Pagano F, Ajassa C, Brunelli R, Terrin G. Liver Involvement in SARS-CoV-2 Vertically Infected Newborn: A Case Report. *Front Pediatr* 2021; **9**: 701722 [PMID: 34858898 DOI: 10.3389/fped.2021.701722]

55 **Vivanti AJ**, Vauloup-Fellous C, Prevot S, Zupan V, Suffee C, Do Cao J, Benachi A, De Luca D. Transplacental transmission of SARS-CoV-2 infection. *Nat Commun* 2020; **11**: 3572 [PMID: 32665677 DOI: 10.1038/s41467-020-17436-6]

56 **Guan WJ**, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; **382**: 1708-1720 [PMID: 32109013 DOI: 10.1056/NEJMoa2002032]

57 **Mallet V**, Beeker N, Bouam S, Sogni P, Pol S; Demosthenes research group. Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020. *J Hepatol* 2021; **75**: 848-855 [PMID: 33992699 DOI: 10.1016/j.jhep.2021.04.052]

**Footnotes**

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** September 13, 2022

**First decision:** September 29, 2022

**Article in press:** January 3, 2023

**Specialty type:** Virology

**Country/Territory of origin:** Iran

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Liu Y, China; Naswhan AJ, Qatar; Skrypnik D, Poland **S-Editor:** Liu GL **L-Editor:** A **P-Editor:** Liu GL

**Figure Legends**

****

**Figure 1 Summary of liver injury in coronavirus disease 2019 patients.** ACE2: Angiotensin-converting enzyme 2.

****

**Figure 2 Summary of liver injury of coronavirus disease 2019 according to the age of patients.**



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +19253991568

**Email:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**